Loading clinical trials...
Loading clinical trials...
The objective of this study is to develop artificial intelligence (AI) tools to characterize cardiac remodelling in arterial hypertension through the analysis of routine imaging data (echocardiography) coupled with patient data. More precisely, this study will make it possible (i) to represent in a relevant way the spectrum of the cardiac repercussions of a population affected by hypertension to better characterize the progress of the pathology, in particular vis-à-vis the more ambiguous subjects to be characterized ("grey" area); (ii) to develop tools for the automatic quantification of cardiac function (segmentation and robust monitoring of the myocardium during the cardiac cycle, for the dynamic analysis of the shape and global deformation of the heart) and therefore to extract descriptors richer in cardiac function than those currently used in clinical routine.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Hopital Lyon Sud
Pierre-Bénite, France
Start Date
June 1, 2022
Primary Completion Date
December 31, 2022
Completion Date
December 31, 2024
Last Updated
November 8, 2024
200
ESTIMATED participants
Clinical cardiac parameters (Arterial pressure, number of anti-hypertensive medications, and the NT-proBNP measurements)
OTHER
Lead Sponsor
Hospices Civils de Lyon
NCT06649110
NCT07218029
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06481852